Yukie Yoshii

Enhanced Radionuclide Therapy via the Conjugation of Pentadecanoic Acids With 225 Ac ‐ and 177 Lu ‐Labeled RGD Peptides

Mitsuyoshi Yoshimoto, Shun‐ichi Wada, Yukie Yoshii, Sayaka Hanadate et autres

ABSTRACT Improved peptide pharmacokinetics are needed to enhance the therapeutic effects of peptide‐based radionuclide therapy. Conjugation of albumin binders, such as fatty acids, to tumor‐targeting peptides slows blood clearance, resulting in higher tumor uptake. In this study, we synthesized PD‐conjugated monomeric and …

jp (code pays fourni par la source)

Preclinical evaluation of 64Cu-labeled cetuximab in immuno-PET for detecting sentinel lymph node metastasis in epidermal growth factor receptor-positive breast cancer

Takeshi Usui, Tomohiro Miyake, Tadashi Watabe, Hiroki Kato et autres

Despite advances in breast cancer imaging, reliable detection of sentinel lymph node (SLN) metastasis remains challenging. This study aimed to determine the ability of immuno-positron emission tomography (PET) using 64 Cu-labeled cetuximab to detect SLN metastasis in a model of epidermal growth …

jp (code pays fourni par la source)

Efficacy of radioactive hypoxia-targeting therapeutic agent 64Cu-ATSM on recurrent malignant glioma: a study protocol for a phase-III, investigator-sponsored, randomized controlled trial

Yayoi Ando, Shunsuke Yanagisawa, Makoto Ohno, Hiroaki Kurihara et autres

Previously, we conducted the phase I study of 64Cu-ATSM, which is Cu-diacetyl-bis (N4-methylthiosemicarbazone) radiolabeled with Cu-64, for patients with brain tumors and determined the maximum tolerated dose. We started a subsequent multicenter, randomized, open-label phase III study to evaluate the efficacy of …

us, gb, jp (code pays fourni par la source)

64Cu2+ Complexes of Tripodal Amine Ligands’ In Vivo Tumor and Liver Uptakes and Intracellular Cu Distribution in the Extrahepatic Bile Duct Carcinoma Cell Line TFK-1: A Basic Comparative Study

Mitsuhiro Shinada, Masashi Takahashi, Chika Igarashi, Hiroki Matsumoto et autres

Copper (Cu) is a critical element for cancer cell proliferation and considerably accumulates in the nucleus. 64Cu2+ is an anticancer radiopharmaceutical that targets the copper requirement of cancer cells. However, intravenously injected 64Cu2+ ions primarily accumulate in the liver. Ligand complexation of …

jp (code pays fourni par la source)

Phase I clinical trial of 64Cu-ATSM for malignant brain tumors.

Hiroaki Kurihara, Yoshitaka Narita, Kimiteru Ito, Hidemitsu Sato et autres

2052 Background: Malignant brain tumors such as glioblastoma have poor prognosis. Current standard therapies such as surgery, radiotherapy, and chemotherapy were frequently insufficient. Hypoxic tissue microenvironments induced by rapid cellular growth within tumor lesions lead to treatment resistance. Methods: Eligible patients had …

jp (code pays fourni par la source)

64Cu2+ Complexes of Tripodal Amine Ligands on In Vivo Tumor and Liver Uptake and Intracellular Cu Distribution in the Extrahepatic Bile Duct Carcinoma Cell Line TFK-1: A Basic Comparative Study

Mitsuhiro Shinada, Masashi Takahashi, Chika Igarashi, Hiroki Matsumoto et autres

Copper (Cu) is a critical element for cancer cell proliferation and considerably accumulates in the nucleus. 64Cu2+ is an anticancer radiopharmaceuticals targeting the copper requirement of cancer cells. However, intravenously injected 64Cu2+ ions primarily accumulate in the liver. Ligand complexation of 64Cu2+ …

jp (code pays fourni par la source)

Trace Metal Impurities Effects on the Formation of [64Cu]Cu-diacetyl-bis(N4-methylthiosemicarbazone) ([64Cu]Cu-ATSM)

Mitsuhiro Shinada, Hisashi Suzuki, Masayuki Hanyu, Chika Igarashi et autres

[64Cu]Cu-diacetyl-bis(N4-methylthiosemicarbazone) ([64Cu]Cu-ATSM) is a radioactive hypoxia-targeting therapeutic agent being investigated in clinical trials for malignant brain tumors. For the quality management of [64Cu]Cu-ATSM, understanding trace metal impurities’ effects on the chelate formation of 64Cu and ATSM is important. In this study, we …

jp (code pays fourni par la source)

An In Vivo Dual-Observation Method to Monitor Tumor Mass and Tumor-Surface Blood Vessels for Developing Anti-Angiogenesis Agents against Submillimeter Tumors

Tomoko Tachibana, G. Isoyama, Yukie Yoshii, Fukiko Hihara et autres

Managing metastasis at the early stage and detecting and treating submillimeter tumors at early metastasis are crucial for improving cancer prognosis. Angiogenesis is a critical target for developing drugs to detect and inhibit submillimeter tumor growth; however, drug development remains challenging because …

jp (code pays fourni par la source)

10247-ET-8 HHYPOXIA-TARGETING RADIOPHARMACEUTICAL 64CU-ATSM FOR PET MONITORING WITH LOCAL THERAPY IN HIGH-GRADE GLIOMA PATIENT-DERIVED XENOGRAFT MODEL

Kensuke Tateishi, Fukiko Hihara, Akito Oshima, Tetsuya Yamamoto et autres

Abstract High-grade gliomas (HGGs) are highly aggressive brain cancers characterized by the presence of hypoxia within a rapidly-growing tumor mass. Due to invasion to the surrounding brain parenchyma, these tumors commonly recur locally,, and novel local approaches are required. Here, we show …

jp (code pays fourni par la source)

Process to Remove the Size Variants Contained in the Antibody–Chelator Complex PCTA-NCAB001 for Radiolabeling with Copper-64

Yukie Yoshii, Hiroki Matsumoto, Chika Igarashi, Tomoko Tachibana et autres

Understanding the physicochemical properties of antibody–drug conjugates is critical to assess their quality at manufacturing and monitor them during subsequent storage. For radiometal–antibody complexes, it is important to control the properties of the antibody–chelator conjugate to maintain the quality of the final …

jp (code pays fourni par la source)

Data from A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma

Kensuke Tateishi, Yohei Miyake, Masahito Kawazu, Nobuyoshi Sasaki et autres

Abstract Primary central nervous system lymphoma (PCNSL) is an isolated type of lymphoma of the central nervous system and has a dismal prognosis despite intensive chemotherapy. Recent genomic analyses have identified highly recurrent mutations of MYD88 and CD79B in immunocompetent PCNSL, whereas …

jp, us (code pays fourni par la source)

Supplementary Data from A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma

Kensuke Tateishi, Yohei Miyake, Masahito Kawazu, Nobuyoshi Sasaki et autres

Supplementary document